86 related articles for article (PubMed ID: 7335366)
1. New regimen of combination hormone therapy (ME-TA-MAP) in the treatment of advanced breast cancer. A pilot study.
Pannuti F; Martoni A; Fruet ; Marraro D; Strocchi E
Panminerva Med; 1981; 23(3):157-60. PubMed ID: 7335366
[No Abstract] [Full Text] [Related]
2. Combination therapy with progestins and tamoxifen in advanced breast cancer: A preliminary report.
Trodella L; Ausilli-Cefaro GP; Turriziani A; Saccheri S; Venturo I; Minotti G
Am J Clin Oncol; 1982 Oct; 5(5):495-9. PubMed ID: 6217741
[No Abstract] [Full Text] [Related]
3. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulation-fibrinolytic systems in patients with advanced breast cancer.
Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
Acta Oncol; 1993; 32(5):573-4. PubMed ID: 8217244
[No Abstract] [Full Text] [Related]
4. [Endocrine treatment of metastasizing breast cancer in menopausal women. A randomized comparison between tamoxifen (Nolvadex) versus tamoxifen and medroxyprogesterone acetate (Clinovir)].
Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt J; Rose C
Ugeskr Laeger; 1979 Jul; 141(31):2113-6. PubMed ID: 483409
[No Abstract] [Full Text] [Related]
5. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
[TBL] [Abstract][Full Text] [Related]
6. Ethinyl estradiol and medroxyprogesterone treatment in advanced breast cancer: a pilot study.
Pellegrini A; Massidda B; Mascia V; Ionta MT; Lippi MG; Muggiano A; Carboni E; Robustelli della Cuna G; Bernardo G; Strada MR; Pavesi L
Cancer Treat Rep; 1981; 65(1-2):135-6. PubMed ID: 7226163
[TBL] [Abstract][Full Text] [Related]
7. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
8. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
[No Abstract] [Full Text] [Related]
9. A pilot study of a high dose methotrexate regime in the management of advanced breast cancer.
Penney GC; Roberts MM
Clin Oncol; 1980 Dec; 6(4):385-6. PubMed ID: 7460412
[No Abstract] [Full Text] [Related]
10. [Effects of combined hormone therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer].
Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
Gan To Kagaku Ryoho; 1993 May; 20(7):957-9. PubMed ID: 8489302
[No Abstract] [Full Text] [Related]
11. [Adjuvant endocrine therapy of breast cancer].
Jonat W; Maass H
ZFA (Stuttgart); 1983 Apr; 59(10):571-4. PubMed ID: 6868762
[No Abstract] [Full Text] [Related]
12. Weight loss during therapy for advanced breast cancer.
Rowland-Payne CM; Abbott M; Jones JM; Powles TJ; Coombes RC
Clin Oncol; 1982 Mar; 8(1):33-8. PubMed ID: 7075043
[No Abstract] [Full Text] [Related]
13. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
[No Abstract] [Full Text] [Related]
14. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).
Beex L; Rose C; Mouridsen H; Jassem J; Nooij M; Estape J; Paridaens R; Piccart M; Gorlia T; Lardenoije S; Baila L
Eur J Cancer; 2006 Dec; 42(18):3178-85. PubMed ID: 17045796
[TBL] [Abstract][Full Text] [Related]
15. [A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
Yamaguchi S; Fukuda M; Ota T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1145-52. PubMed ID: 10431580
[TBL] [Abstract][Full Text] [Related]
16. [Metastatic breast carcinoma: sequential hormonotherapy with tamoxifen and medroxy-progesterone acetate. preliminary results].
Bosset JF; Pereal M; Hurteloup P; Altwegg T; Del Piano F; Colette C; Schraub S
Bull Cancer; 1982; 69(2):170-1. PubMed ID: 7126890
[No Abstract] [Full Text] [Related]
17. [Chemotherapy in advanced breast cancer: experience in 100 cases (author's transl)].
Modolell Roig A; Sans-Sabrafen J; Pardo Peret P; Rodríguez Ferrera JC; Boleda Relats M; Buxó Costa J; Galofré Folch M
Med Clin (Barc); 1982 Mar; 78(6):211-7. PubMed ID: 7087579
[No Abstract] [Full Text] [Related]
18. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Jenkins V; Shilling V; Fallowfield L; Howell A; Hutton S
Psychooncology; 2004 Jan; 13(1):61-6. PubMed ID: 14745746
[TBL] [Abstract][Full Text] [Related]
19. [Overall evaluation of the results of treatment of metastatic carcinomas of the breast with high doses of MAP combined with bromocryptin].
Mussa A; Dogliotti L; Di Carlo F
Minerva Med; 1980 Feb; 71(6):391-400. PubMed ID: 7360379
[No Abstract] [Full Text] [Related]
20. [Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages].
Pannuti F; Di Marco AR; Martoni A; Fruet F; Strocchi E; Burroni P; Marraro D
Minerva Ginecol; 1982 Nov; 34(11):977-9. PubMed ID: 7155427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
